Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 May;103(6):963-971.
doi: 10.1002/ccd.31028. Epub 2024 Apr 2.

A multicenter prospective observational study appraising the effectiveness of the Supera stent after subintimal recanalization of femoro-popliteal artery occlusion: The SUPERSUB II study

Affiliations
Observational Study

A multicenter prospective observational study appraising the effectiveness of the Supera stent after subintimal recanalization of femoro-popliteal artery occlusion: The SUPERSUB II study

Luis Mariano Palena et al. Catheter Cardiovasc Interv. 2024 May.

Abstract

Background: Complex femoropopliteal artery disease represents a challenge. The Supera stent holds the promise of improving the results of endovascular therapy for complex femoropopliteal disease.

Aims: We aimed at appraising the early and long-term effectiveness of the Supera stent after successful subintimal angioplasty (SuperSUB strategy) for complex femoropopliteal lesions.

Methods: We conducted a multicenter, prospective, single-arm observational study including consecutive patients at participating centers in whom Supera was implanted after successful subintimal angioplasty for complex femoropopliteal lesions.

Results: A total of 92 patients were included Femoropopliteal arteries were the most common target, and lesion length was 261 ± 102 mm. Most procedures were technically demanding, with antegrade femoral access in 35 (38%) and retrograde distal access in 55 (60%). Supera stent length was 281 ± 111 mm, with 4, 5, and 6 mm devices being most commonly used: 32 (35%), 35 (38%), and 23 (25%), respectively. Technical success was achieved in 100% of subjects, as was clinical success (per subject), whereas procedural success (per subject) was obtained in 98%. At 24 months, freedom from clinically driven target lesion revascularization was 93%, whereas primary patency was 87%. When compared with a similar historical cohort, Supera stent use appeared to be associated with a reduction in resources.

Conclusion: Use of Supera stent after successful subintimal recanalization of complex lower limb arterial lesions yields favorable procedural results, which are maintained over follow-up, and are associated also with a favorable resource use profile.

Trial registration: ClinicalTrials.gov NCT00933270.

Keywords: Supera stent; endovascular therapy; femoropopliteal disease; peripheral artery disease; stent; subintimal angioplasty.

PubMed Disclaimer

References

REFERENCES

    1. Shi R, Babu S. Modern approaches and innovations in the diagnosis and treatment of peripheral vascular diseases. Front Biosci (Schol Ed). 2021;13:173‐180.
    1. Saglietto A, Manfredi R, Elia E, et al. Cardiovascular disease burden: Italian and global perspectives. Minerva Cardiol Angiol. 2021;69:231‐240.
    1. Aru RG, Tyagi SC. Endovascular treatment of femoropopliteal arterial occlusive disease: current techniques and limitations. Semin Vasc Surg. 2022;35:180‐189.
    1. Ferraresi R, Palena LM, Mauri G, Manzi M. Tips and tricks for a correct “endo approach”. J Cardiovasc Surg. 2013;54:685‐711.
    1. Giannopoulos S, Armstrong EJ. Newly approved devices for endovascular treatment of femoropopliteal disease: a review of clinical evidence. Expert Rev Cardiovasc Ther. 2019;17:729‐740.

Publication types

MeSH terms

Associated data